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Abstract
Background: Current World Health Organization (WHO) guidelines recommend early initiation of HIV positive
patients on antiretroviral therapy (ART) irrespective of their clinical or immunological status known as the test and
start approach. Lesotho, like many other countries introduced this approach in 2016 as a strategy to reach epidemic
control. There will be rapidly growing number of HIV-infected individuals initiating treatment leading to practical
challenges on health systems such as congestion, long waiting time for patients and limited time to provide quality
services to patients. Differentiated models of ART delivery is an innovative solution that helps to increase access to
care, while reducing the burden on existing health systems. Ultimately this model will help to achieve retention
and viral suppression. We describe a demonstration study designed to evaluate a community-based differentiated
model of multi-month dispensing (MMD) approaches of ART among stable HIV patients in Lesotho.
Methods: This study will be a three-arm cluster randomised trial, which will enrol approximately 5760 HIV-infected
individuals who are stable on ART in 30 selected clusters. The clusters, which are health facilities, will be randomly
assigned into the following differentiated model of care arms: (i) 3 monthly ART supply at facilities (Control), (ii) 3
monthly ART supply through community ART groups (CAGs) and (iii) 6 monthly ART supply through community
ART distribution points (CAD). Primary outcomes are retention in care and virologic suppression, and secondary
outcomes include feasibility and cost effectiveness.
Discussion: Important lessons will be learnt to allow for improved implementation of such demonstration projects,
including various needs for reliable supply of medication, access to quality clinical data including access to viral
loads (VLs) results, frameworks to support lay worker cadre, involvement of community stakeholders, and reliable
data systems including records of key indicators. MMD will have positive implications including improved retention,
virologic suppression, convenience and access to medication.
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Background
Lesotho is undergoing a significant health transition
characterised by high burden of infectious diseases such
as HIV/AIDS, tuberculosis and an emergence of
non-communicable diseases [1]. Among adults, HIV
prevalence in Lesotho is reported to be 25% and 53% of
adults are receiving antiretroviral treatment (ART) [2].
An estimated 310,000 people were living with HIV and
18,000 died from AIDS related issues in 2015 [3]. PEP-
FAR adopted the UNAIDS 90–90-90 targets and the
new WHO guidelines on when to initiate ART [4]. The
WHO guidelines recommend ART initiation immedi-
ately after testing positive, regardless of CD4 count, with
lifelong continuation to warrant and improve individual
‘s health and reduce HIV transmission [5]. To realize the
full benefits of this approach, high levels of adherence
and retention are needed. In low to middle income
countries (LMICs) including Lesotho, long waiting times
in ART clinics, cost of travel to clinics and other life
commitments are known to disrupt and reduce the
adherence and retention levels. A need for monthly
dispensing and/or systems that require multiple separate
visits for refills and clinical evaluations can raise signifi-
cant challenges for people living with HIV (PLHIV) and
result in treatment interruptions or complete disengage-
ment from care [6]. Hence, extending of interval ART
refills may improve outcomes, if supply can be guaran-
teed for up to six months for stable patients in low
resourced settings.
Currently, many LMICs including Lesotho dispense
ART monthly which places demands on the health system
and can lead to suboptimal adherence and disengagement
in care due to the time and cost of frequent visits to clinic.
There is need to implement novel strategies for ART
dispensing to enable health systems cope with the
ever-increasing number of HIV patients needing care and
treatment. A gap exists in allowing stable patients to have
an adequate and longer-term supply of ART especially if
this does not compromise outcomes of interest including
retention and viral load (VL) suppression.
Community based models of care i.e. CAGs are postulated
to further strengthen adherence, retention and viral suppres-
sion. These models give peer support among patients. CAGs
have been successfully implemented in Lesotho and introdu-
cing MMD into them can have the same intended outcomes
as facility-based interventions, whilst additionally decongest-
ing and decentralising facilities.
Potential benefits for this approach includes (i) higher
adherence to ART and retention in care, (ii) reduced
per-patient cost of providing ART, by reducing the
number of clinic visits required, (iii) decongestion of
clinics to allow for increased capacity to manage patients
newly diagnosed with HIV, those with infectious compli-
cations, treatment failure, and other co-morbidities and
(iv) decreased waiting time and improved efficiency at
clinics allowing for improved quality of care and patient
satisfaction [7, 8].
Limited data are available from LMICs on multi-month
scripting and dispensing and on studies using community
-based models of care. A review of the literature reveals a
lack of randomized studies of different ART dispensing
intervals. An abstract presented at the Conference on Retro-
viruses and Opportunistic Infections, 2016 using Zambian
data, suggested that requirements for monthly dispensing
and/or systems that require multiple separate visits for refills
and clinician evaluation can raise significant challenges for
people living with HIV and result in treatment interruptions
or complete disengagement from care [6].
This study’s primary objectives are (i) to determine if
stable patients receiving 3 monthly dispensing of ART
within CAGs have non-inferior retention in care and viral
load suppression than stable ART patients receiving 3
monthly dispensing at health facilities after 12 and
24 months, (ii) 6 monthly dispensing of ART within the
community from a health care worker have non-inferior
retention in care than stable ART patients receiving 3
monthly dispensing at health facilities after 12 and
24 months and (iii) 6 monthly dispensing of ART within
the community from a healthcare worker have non-inferior
retention in care than stable ART patients receiving 3
monthly dispensing within CAGs after 12 and 24 months.
The secondary objectives are to compare cost outcomes
(cost per patient retained and cost per patient retained with
viral suppression) between the three models, investigate the
acceptability of 3 and 6 monthly community-based ART
distribution among patients and service providers and to
assess if there are measurable gains in clinic productivity
realized following the introduction of community based
MMD of ART.
Methods/design
Setting
This study will include 30 health facilities (clusters) pur-
posely selected from Maseru, Mafeteng and Mohale’s Hoek
districts. These districts have been purposively selected due
to (i) high numbers of patients on ART, (ii) has established
and have since prioritised CAGs (iii) ability to perform VL
determination as part of routine care. Facilities are to be
included in the study if they have implemented or have
systems in place for CAGs or community ART dispensing
(CAD) through a healthcare worker, CAGs and CAD
points are feasible within the health facilities community,
health facility routine data collection and systems are in
place, completeness of medical records, ability to perform
VL determination as part of routine care, existing drug
supply chain procedures for multi-month dispensing, and a
large enough population to enrol stable ART patients.
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Study design
The study will be a pragmatic, three arm, parallel, cluster
-randomized non-inferiority design. The thirty facilities
(clusters) will be randomly assigned to three arms (Fig. 1)
with patients receiving (i) 3MF- 3 monthly ART supply at
facilities (Control), (ii) 3MC - 3 monthly ART supply
through community ART groups (CAGs) and (iii) 6MCD -
6 monthly ART supply through community distribution
points (CAD). Included facilities will be randomized, with
stratification by whether the facility is in a rural or urban
setting according to the Lesotho Bureau of Statistics’ data.
After this process, each arm will, contain 10 facilities.
Study population and eligibility
This study will be conducted among approximately 5760
HIV-infected individuals who are stable on ART in 30
selected clusters. The eligibility criteria of participants
are tabulated in Table 1.
Study procedures: recruitment, screening and enrolment
processes
Recruitment methods for this study will be comparable
across clusters (health facilities) and are expected to rely
on active identification and referral of stable patients, as
defined in the inclusion criteria above through relevant
study staff. Facilities will be randomized to either of the
3 arms and individuals will receive their first drug sup-
plies to which the cluster has been randomly assigned at
enrolment. However, after first dispensing of drugs at
the facility, those randomized to the arm to which pa-
tients are to receive 3 and 6 monthly ART supply
through CAGs and CAD will respectively receive their
next ART refills through these community approaches
and platforms. Only those randomized to the 3 monthly
ART-supply at facilities will receive their next ART refill
within facilities.
The process of consenting participant’s will be fully
documented, and only individuals who are able to dem-
onstrate understanding will be asked to provide written
informed consent for study screening and enrolment.
All patients potentially eligible for the study would
also be eligible for a VL test per the national ART guide-
lines if they had not previously had one in the last
12 months. Once the VL result is back, they will be
re-screened for study eligibility when they return for
their next routine visit. After enrolment into study,
co-enrolment in other studies will not be allowed given
the likelihood that this could interfere with the primary
study endpoint of retention.
Participant retention and withdrawal or termination from
the study
As retention in care is a primary outcome for the study,
once an individual is enrolled, there will be no additional
efforts applied towards retaining them except for standard
of care counselling and routine retention support offered
by sites as per national guidelines. Study interactions with
participants will be minimized through use of existing
medical records to track patient outcomes. We will obtain
informed consent to contact people after completion of
the study to perform qualitative interviews and surveys of
acceptability, cost and quality of life measures. Regardless
of the participant retention procedures referenced above,
individuals may voluntarily withdraw from the study.
Fig. 1 Multi-Month Community Dispensing of ART: Examining the Role of Differentiated models of ART Supply on Retention and
Virologic Suppression
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Study intervention: differentiated models of care for
MMD of ART
Three month dispensing model at health facilities
Providers at facilities randomized to three-month
dispensing will be expected to provide all enrolled
patients with a 3-month supply of ART. All other
aspects of care will be as standard of care for the
enrolling clinic, though routine clinic visits will occur
every 90 days instead of the standard of care interval.
Information about ideal storage conditions for ART
will be provided by the clinic.
Community ART group (CAG) model (3-month supply of drug)
Study participants enrolled at facilities in this arm will join
new or previously existing CAGs or will already be mem-
bers of a CAG. Their first 3-month supply of drugs will be
at enrolment facility, whilst the next ART refills will be
through CAGs. The CAG will consist of 4–12 partici-
pants, who live in a similar geographic location and who
all attend the same health care facility. The members’ ap-
pointments will be synchronized to ensure their scheduled
clinic visits will be on the same day. The CAG will nomin-
ate a CAG leader and will meet on a 3-monthly basis in
the community at a venue of their choice to access treat-
ment. Stable study participants will be required to have a
clinical consultation and VL testing at the facility at 12
and 24 months after enrolment in the study. Each mem-
ber of the CAG will collect their own 3-month supply of
ART from the clinic on this day. Participants who become
ill at any stage of the study will report to the clinic as soon
as possible. A CAG representative will distribute the drugs
to the other CAGs members at the CAG meeting on the
same day or the following day. The dates of these visits
need to be noted by the facility so that all drugs are
pre-dispensed and ready at this visit date.
Community ART distribution model by healthcare worker
(6-month supply of drug)
Participants enrolled at facilities in this arm will be given
a 6 months’ supply of their ARVs at study enrolment.
Their next ART refill will be conducted in 6 months in
the community at a health outreach or health post (halls,
churches or kiosks). These encounters in the community
will be on an individual provider-patient basis, not as
part of a CAG. The ART refill will be conducted by a
healthcare worker who has been appropriately trained
and certified for dispensing ART to stable patients.
Study participants’ adherence will be assessed at this
community distribution point as well as screening for
TB, pregnancy, and other common conditions. Patients
found to have any conditions that cannot be managed in
the community will be referred to the health facility for
further follow-up. These participants will continue to re-
ceive 6 month refills in the community if they remain
stable (i.e. have VL less than 1000 copies per mL). Stable
participants will be required to have a clinical consult-
ation and VL done at the facility at 12 months and
24 months after enrolment.
Co-trimoxazole (CPT) and isoniazid (IPT) will also be
provided to all arms based on the assigned ART dispens-
ing interval and Lesotho guidelines.
Study measures and outcomes (data collection matrix)
The schedule of visits and evaluations to be done are out-
lined see Additional file 1. The primary outcomes to be
compared between arms for this study are retention and
VL suppression. Secondary outcomes will include the
following (i) comparisons in cost effectiveness between
arms, (ii) acceptability of models to patients and service
providers and (iii) measurable gains in decongestion in
facilities through motion time assessments/analysis.
Table 1 Eligibility criteria for participants
To be included are those:
(i) 18 years of age or older and willing to provide written informed consent,
(ii) willing to participate in the MMD model (arm) that the patient’s study cluster has been randomized to
(iii) On ART ≥ 6 months with no periods of defaulting on treatment since the last VL result (ART default defined as missing 7 or more consecutive days of ART
(iv) On first-line ART regimen (substitutions within the first-line regimen prior to the last VL test are permissible)
(v) No ARV drug substitutions since the last VL result < 1,000 copies/ml and plasma or dried-blood spot VL < 1,000 copies/ml in a patient who has
been on first-line ART for at least 6 months, with VL drawn within last 12 months of enrolment while patient is receiving ART
To be excluded are those:
(i) on any other ART line regimen
(ii) with co-morbidities requiring more frequent facility visits
(iii) ART substitutions since last VL test (iv) diagnosed with a WHO clinical stage 3 or 4 condition within the past 3 months
(iv) pregnant or less than 12 months postpartum and breastfeeding mothers
(v) participating in another study that involves dispensing interval, adherence, or retention or involves receiving medications
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Entry visit/baseline procedures
For those that enrol, the following detailed data will be col-
lected and recorded from clinical and medical record re-
view: HIV history, HIV-related medications, date of ART
initiation, prior adherence/VL data, socio-demographic data
including age, gender, level of education, estimated distance
and time to travel to clinic, employment status, disclosure
status and marital status. Costing data (patient cost data)
including travel costs to clinic, opportunity cost of time
spent on medication pickup visits etc., will be recorded.
Viral load testing for enrolled patients (at 12 and
24 months)
As the study will be using VL results from routine moni-
toring as an inclusion criterion, some participants will
have a VL test due soon after enrolment into the study.
To synchronize patient care and study VL tests, due rou-
tine VL tests will be done as scheduled unless the test is
due at 2 months before or after the required
study-specific VL test at 12 and 24 months for the study,
in which case the study-specific VL will be used for pa-
tient management. At 12 and 24 months after enrolment
in the study, all patients are required to visit the facility
for a VL test.
In this study, there will be no active contact with study
participants during the period of follow-up. However,
when participants are due for the above-mentioned rou-
tine, annual VL assessments, study staff will help ensure
each site has capacity to collect these samples and will
support systems that help to provide results back to
sites. VLs will only be performed on individuals who re-
turn for visits and no tracing will be performed by the
study for obtaining annual VLs. VLs will be considered
within the window for the annual visit if they are per-
formed in a window of +/− 90 days.
Study end points and definitions
Endpoints will be determined by record reviewing. The
primary endpoint will be reached (12 months) and
re-assessed after the 24-months. Endpoint data collec-
tion will include:
(i) Retention in care defined as participant attrition,
where attrition is defined as either death (all-cause)
or loss to follow-up (LTFU). LTFU will be defined
as no facility or ART collection for > 90 days after
the last missed scheduled ART collection. Participants
with documented transfers to another clinic will be
considered retained at the next immediate time point
(12 or 24 months), and will then be censored.
(ii) Suppressed VL of < 1000 copies/mL done as part of
annual VL or performed at any other time during
the follow-up, if ordered by clinician due to clinical
concern (secondary).
The following will be considered not retained unless
otherwise noted:
(i) Retained in care but with transitioned off assigned
study arm for any reason (patient preference,
provider preference, development of ART toxicity
requiring switch and closer monitoring and any
other complications)
(ii) Transferred to another clinic (if a documented
transfer, will be considered retained and analysed as
such at the next assessment point.
(iii)Death.
Management of patients who develop comorbidities and
those that become pregnant
Participants who develop TB, other opportunistic infec-
tions or comorbidities may require more frequent
follow-ups than required by their dispensing interval. If
they are in the 3MC or 6MCD arm, they will be consid-
ered unstable and are to be followed up at the facility
hence transitioned off the study arm. These individuals
will remain in observational follow-up but considered
not retained for analyses. Providers will make these deci-
sions and the study will track such outcomes. Frequency
of ART dispensing will be determined based on national
guidelines and clinician assessment. These events will be
captured through patient routine records. Women who
become pregnant whilst in the study will also require
more frequent clinical visits for antenatal and postpar-
tum care than required by their dispensing interval. If
they are in the 3MC or 6MCD arm, they will return to
be followed up at the facility. Frequency of ART dispens-
ing will be determined based on national guidelines for
ART in pregnancy and clinician assessment. These
events will be captured through patient routine records.
These individuals will remain in observational follow-up.
Secondary outcomes
Time motion analysis
Regarding assessing the gains of facility decongestion, a
pre- and 24-month post survey time-flow evaluation of
patient waiting times will be conducted. These evalua-
tions will be done over 5 days at each of the 30 facilities.
These data will be collected using a study-specific time
flow recording sheet for all patients visiting the facility
during these 5 days. Mean total visit time, mean waiting
time to be seen by the clinician and mean time for drugs
to be dispensed will be calculated. Additionally, the
monthly number of non-pregnant adults > 18 years
‘newly initiated on ART and receiving ART and
provider-initiated counselling and testing at study facil-
ities will be captured from facility records over the study
duration to determine trends.
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Feasibility of MMD of ART in CAGs and community distribution
The feasibility assessment and analysis will include tech-
nical, resource and structural aspects. Data will be col-
lected prospectively on study-specific forms at the
beginning of the study,12 and 24 months. Before the
study activates, facilities will be assessed on their ability
to do essential medicine quantifications and forecasting.
Each facility’s ability to generate quality data (measured
by pre-determined criteria) and to ensure constant sup-
ply of medicines to the study participants through effi-
cient ordering and delivery processes will be assessed.
Feasibility will also be analysed by the ability of facilities
to source adequate storage facilities, utilize efficient
transportation systems and the turnaround time for or-
dering of medicines. For those within CAGs, attendance
registers will be used to get a sense of individuals partici-
pating rates.
Qualitative data collection
Qualitative data will be collected at baseline, 12 and
24 months. Primarily, it will be to explore the acceptabil-
ity of CAGs and community ART distribution by pa-
tients and service providers, patient satisfaction and
improvement in quality of care at the facilities. Focus
group discussions (FGD) with study participants in the
3MC and 6MCD arms will be held to explore the range
of issues regarding acceptability of CAGs and commu-
nity ART distribution. Each facility will conduct one
FGD with up to 10 study participants at each data col-
lection point. A total of 20 FGD will be held at each data
collection point. Key informant interviews (KII) will be
done with service providers including the facility man-
ager and healthcare workers. Each of the 20 facilities will
have a key informant selected for the interviews. A total
of 20 KII will be collected for the study at each data col-
lection point.
This will give a total of 40 data points for analysis for
the qualitative research. It is hoped that a saturation of
findings will be reached by this sample size. Data will be
collected by trained facilitators in each FGD using
piloted discussion and interview guides for the FGD and
the KII respectively. Each FGD will be conducted by 1
facilitator and 1 note taker, whilst KII will be conducted
by 1 interviewer. Data collection for FGD will be in
Sesotho and it is assumed that all service providers are
conversant in English. All qualitative data will be
recorded, transcribed, translated to English and coded.
All participant in FGDs and KIIs will be required to sign
consent to participate and to be recorded.
Costing and cost-effectiveness
A micro-costing approach, also known as the bottom-up
method will be used. This will allow the tracking of
every input in carrying out the study interventions.
However, this approach will be supplemented by a
macro-costing approach of fixed costs such as infra-
structure, building, equipment, utilities etc. To ascertain
the cost to provider, we will estimate the fixed and vari-
able costs to care. Fixed cost to patients will include (i)
equipment and vehicles (ii) building and Infrastructure
and (iii) administration costs and other above point
-of-care costs. As for variable costs, these will include but
not limited (i) outpatient care (type and number of visits)
(ii) Inpatient care (number of bed days in care) (iii) other
services (ARTs, laboratory tests, non-ART drugs, consum-
ables etc.).
Patient level costing, also known as direct non-medical
costs will also be collected. These costs are borne by
either the patient or relatives of the patient to improve
the care towards the patient. This study intervention is
expected to result in patient level benefits such as
reduced cost for care seeking, productivity benefits due
to reduced time spent seeking care and informal care
effects. Data to assess patient level costs will be collected
from a randomly selected sub-sample of patients from
each arm. Costing outcomes will include:
(i) average cost per patient retained in care and virally
suppressed at 12 and 24 months (cost per patient
retained)
(ii) annual cost per patient in each cohort/arm (per
patient year cost)
(iii)cost-effectiveness of the intervention arms will be
compared with respect to retention in care and
viral suppression.
Safety assessment, monitoring, and reporting
Participant safety will be carefully assessed, monitored
and reported at multiple levels throughout this study.
Site investigators, clinical management committee,
and an independent data and safety monitoring board
will be set up to continuously assess, monitor and
report on all safety related matters. All protocol devi-
ations, or unintended consequences/adverse events re-
lated to the study and its design will be recorded and
appropriately addressed.
Statistical analysis, power and sample size considerations
Descriptive data of the study population stratified by
treatment arm will presented as medians and interquar-
tile ranges for continuous variables and proportions for
categorical variables.
Our analysis will use an intention-to-treat approach in
which generalized estimating equations (GEE) will be
computed to estimate risk differences and risk ratios and
associated 95% confidence interval for the effect of each
intervention arm compared to the control (Patients
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receiving 3 monthly ART supply at facilities), specifying
for clustering by facility. A small cluster size variance
correction will be used. Should we identify any baseline
imbalances between study arms, we will adjust for these
through multivariable regression models and report ad-
justed effect measures and corresponding 95% confi-
dence intervals.
Qualitative analysis will be employed in this study to
ascertain feasibility, acceptability of CAGs and commu-
nity ART distributions by patients and service providers.
Summative content analysis which involves counting
and comparisons of keywords or content, followed by
the interpretation of the underlying context will be con-
ducted. The data will be further analysed for emerging
key themes and the findings will be interpreted based on
each research question. Quotes will also be extracted for
each of the themes that emerge from the data. It is an-
ticipated that MMD will reduce both facility and patient
costs of treatment and that it will be cost-saving com-
pared to standard of care. For facilities, fewer clinic visits
by patients should save the time of providers and sup-
port staff. For patients, fewer clinic visits are expected to
reduce the costs of travel and to save time. The study
will estimate differences in both provider and patient
costs. Cost-effectiveness will be estimated as the average
cost per successful outcome (patient retained at 12 and
24 months).
Sample size estimate
Sample sizes were determined for a cluster randomized
non-inferiority trial with retention in care at 12 months
as the primary outcome. A total of 30 study sites will be
available for randomization, with three study arms, 10
clusters per arm, and participant enrolment numbers
will be assumed to be equal at each site. The probability
of patient attrition 12 months after study enrolment is
assumed to be 5%. An intra-cluster correlation coeffi-
cient of 0.01 for patient retention/attrition amongst
stable ART patients is assumed from a previous cluster
randomized trial including stable ART patients [9]. The
non-inferiority limit is specified as 3.25%. Assuming α =
0.05, power of 85%, and using a one-sided Z-test
(un-pooled) statistic, approximately 192 enrolled partici-
pants per facility will be required with a total sample size of
5760 participants, representing 1920 participants per arm.
Ethical considerations
All participants will receive information about the study
and have opportunity to ask questions. Written in-
formed consent will be obtained from participants after
they receive comprehensive details on (i) the purposes of
the study; (ii) the allocation process; (iii) the use of data
and the means of assuring confidentiality; (iv) voluntary
participation and the participant’s right to withdraw
from the study at any time and (v) any potential harm
that could occur because of the intervention. Consent
will be acquired prior to obtaining any study measure-
ments. The study protocol was developed using the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) Checklist (see Additional file 1) and
adheres to the SPIRIT recommendations. The trial is reg-
istered with ClinicalTrials.gov as NCT03438370 and has
received ethical clearance from the Lesotho National
Health Research Ethics based at the Ministry of Health as
well as Chesapeake Institutional Review Board in the USA
[Number: ID49–2017 and MOD00231007 respectively].
Discussion
In this paper, we present and describe a demonstration
study protocol that will evaluate retention in care, viro-
logic suppression, feasibility and cost effectiveness of
community based differentiated models of MMD ap-
proaches of ART among stable HIV patients in Lesotho.
Community based models for delivering ART have po-
tential of being an integral part of strengthening the
HIV treatment cascade. To meet the UNAIDS targets to
end the AIDS epidemic by 2030, a need exists in diversi-
fying ART delivery in ways that are acceptable to com-
munities and maintaining good outcomes including
retention and viral suppression [4, 10]. However, com-
munity systems must be adequately resourced, including
infrastructure that allows for linking and integration
with health facilities, allowing for better sustainability
and scaling -up.
The WHO has recommended provision of ART through
community models, only if operating guidance and moni-
toring are provided [5]. These strategies are to ultimately
significantly reduce the burden experienced by patients
and health care providers. Though all models, are to
include stable patients, in this context virologically sup-
pressed, and those who are able to adhere to ART [11],
the community multi month dispensing approaches in-
cluding both CAGs and community ART distribution
points have been shown and postulated to provide gains
for patients by (i) reducing time and transport costs
(WHO, 2016), (ii) increasing peer support for adherence
(through clubs and CAGs) [11, 12] (iii) reduced defaulting
and enhancing community participation [5]. Whereas, for
health providers it (i) reduces workload (ii) and maintains
and improves health outcomes and improves self-
management of patients. Additionally, these approaches,
could be extended to key populations including migrants
in Sub Saharan Africa, where patients move away from
their homes for work and other economic reasons [13]. A
study among migrants, assessing healthcare needs, prefer-
ences and accessibility barriers of HIV-positive migrant
patient populations in high disease burden, borderland
districts of Lesotho showed that less than 7% opted for a
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1–2 month ARVs refills [14]. Whereas 30.2%and 63% indi-
cated a preference for 3–4 month and 5–6 month refills
respectively. More than 65% encountered barriers to receiv-
ing their ARVs and about 25% defaulted while abroad [14].
Previous lessons have been learnt to allow for im-
proved management of risk when implementation multi
month dispensing ART projects. We anticipate this will
include a need for reliable supply of medication [15], ac-
cess to quality clinical data and linkages, including VLs
results, frameworks to support lay worker’s cadre [16, 17],
involvement of community stakeholders, and reliable data
systems and records of key indicators. The design to be
used namely a pragmatic, parallel, cluster-randomized
non-inferiority design has the following advantages that
add rigor to findings [18]. Additionally, the non-inferiority
design aims to determine whether a new approach is not
worse than a standard approach by more than a preset
margin [19].
In Lesotho, viral load monitoring is performed annu-
ally for stable adult’s patients on ART. We anticipate
missing viral results. Viral load suppression is thus a sec-
ondary outcome. Our findings will be interpreted with
care when generalizing to other settings, as there are
varying definitions of the term stable patients [20],
which is an inclusion criterion in the current study.
Additionally, we will not ascertain outcomes of unstable
ART patients that will be screened out who may have
potentially benefited from the interventions. Large quan-
tities of drugs will be supplied to those that will enroll in
the 3 and 6-month arms (including ART, CPT and IPT).
This will be challenging for patients who have not dis-
closed their HIV status to family members leading to er-
roneous disclosure of HIV status. There is risk for
patients to share medication with peers. Both partici-
pants and providers will not be blinded, and this might
lead to participants wanting to transfer to another arm.
Regardless of arm, participants are more likely to be
retained if they are aware they are part of a study.
Despite these limitations, this study has a robust de-
sign, it is will be the first randomized study to explore
the outcomes of retention, virologic suppression and
cost effectiveness through differentiated community ART
distribution approaches in Lesotho. The study will provide
important data regarding the effectiveness of community
models for ART distribution and is anticipated to inform
policy regarding best practice among HIV-positive pa-
tients receiving ART and what is needed to strengthen
health systems for rapid scaling up of ART in a contextu-
alized, sustainable and cost-effective manner.
Trial status
Recruitment and enrolment began 7 August 2017 and is
still on going.
Additional file
Additional file 1: Data collection matrix and schedule of events. (PDF
593 kb)
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